Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein | Nature Medicine

Una buena noticia: el virus SARS-CoV-2 tiene su talón de Aquiles; la proteína de la espícula. Además con este panel de anticuerpos neutralizantes se demuestra que una vacuna que estimule estos anticuerpos será efectiva.(jose manuel bautista twitter @1000genes)

https://www.nature.com/articles/s41591-020-0998-x

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

,

10 July 2020

Nature Medicine (2020)Cite this article

• 5831 Accesses
• 315 Altmetric
• Metrics

Abstract

Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date^1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.